Silence Therapeutics plc (SLN)

GB — Healthcare Sector
Peers: CDTX  APLT  CTMX  CELL  STTK  CCCC  ELYM  PRLD  GLUE  OPT  CNTA  NUVL  TARS  GNFT  RNA  IGMS  CERE  CGEM  MLYS 

Automate Your Wheel Strategy on SLN

With Tiblio's Option Bot, you can configure your own wheel strategy including SLN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SLN
  • Rev/Share 0.185
  • Book/Share 1.82
  • PB -2.2662
  • Debt/Equity 0.0005
  • CurrentRatio -8.8138
  • ROIC -0.3844

 

  • MktCap 255515831.0
  • FreeCF/Share -0.4363
  • PFCF -4.1333
  • PE -4.4879
  • Debt/Assets -0.0003
  • DivYield 0
  • ROE -0.8749

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation SLN Goldman -- Sell -- $6 Feb. 11, 2025
Initiation SLN Jefferies -- Buy -- $40 Sept. 3, 2024

News

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
SLN
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Silence Therapeutics (SLN) points to a 590.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
SLN
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting (“AGM”) in June 2025. “We are thrilled to welcome Tim to the Silence Board,” said Iain Ross, Chairman of the Sil.

Read More
image for news Silence Therapeutics Welcomes Tim McInerney to Board of Directors
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
SLN
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Positive

Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript
SLN
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral

Silence Therapeutics plc (NASDAQ:SLN ) Q4 2024 Earnings Call February 27, 2025 8:00 AM ET Company Participants Gem Hopkins - Vice President, Investor Relations and Corporate Communications Craig Tooman - President and Chief Executive Officer Rhonda Hellums - Chief Financial Officer Steven Romano - Chief R&D Officer Conference Call Participants Mike Ulz - Morgan Stanley Kostas Biliouris - BMO Capital Markets Richard Law - Goldman Sachs Keay Nakae - Chardan Myles Minter - William Blair Gem Hopkins Good morning and good afternoon, everyone. Thank you for joining us today.

Read More
image for news Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

About Silence Therapeutics plc (SLN)

  • IPO Date 2020-09-08
  • Website https://www.silence-therapeutics.com
  • Industry Biotechnology
  • CEO Mr. Craig A. Tooman M.B.A.
  • Employees 116

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.